Tesamorelin against NAFLD clinical trial started in Jan 2019
Trial:
https://clinicaltrials.gov/ct2/show/NCT03375788?term=Egrifta+Tesamorelin&cond=NAFLD&rank=2
Notes:
1/ This trial focus on NAFLD in non-HIV population, not NASH, which recruting criteria excludes NASH patients.
2/ This trial is conducted under a NIH grant in May 2018: https://www.globenewswire.com/news-release/2018/05/11/1501001/0/en/Theratechnologies-Announces-That-National-Institutes-of-Health-Will-Support-Study-on-EGRIFTA-Tesamorelin-for-Injection-in-Non-HIV-Patients-With-Non-Alcoholic-Fatty-Liver-Disease.html
3/ The principal investigator is Dr. Takara Stanley, Massachusetts General Hospital.
4/ When NIH gave grant to this study, the previous clinical trial conducted by Dr. Grinspoon has been under way for more than 4 years (see https://clinicaltrials.gov/ct2/show/NCT02196831 ) as this study started in 2014. Probably by 2016, both cohorts on treatment and placebo arms (still blinded) entered open label study with tesamorelin for the next 6 months (ended around 2017). The fact that NIH decided to issue grant for further study in 2018 likely indicates a positive results, since the open label study results should be readily available. If the results were negative, I doubt that NIH would have given grant to further study in non-HIV population.
5/ Final results from Dr Grinspoon trial is scheduled for July 2019.